{"id":100153,"date":"2013-06-03T17:55:44","date_gmt":"2013-06-03T17:55:44","guid":{"rendered":"https:\/\/knome.com\/?p=100153"},"modified":"2024-09-12T13:29:03","modified_gmt":"2024-09-12T13:29:03","slug":"omixon-and-knome-partner-to-offer-advanced-hla-typing-for-whole-genome-and-exome-level-data","status":"publish","type":"post","link":"https:\/\/www.knome.com\/?p=100153","title":{"rendered":"Omixon and Knome Partner to Offer Advanced HLA Typing for Whole Genome and Exome Level Data"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;section&#8221; _builder_version=&#8221;4.27.0&#8243; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_row admin_label=&#8221;row&#8221; _builder_version=&#8221;4.16&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_heading title=&#8221;Omixon and Knome Partner to Offer Advanced HLA Typing for Whole Genome and Exome Level Data&#8221; _builder_version=&#8221;4.27.0&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#E02B20&#8243; title_font_size=&#8221;25px&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221; sticky_enabled=&#8221;0&#8243;][\/et_pb_heading][et_pb_text admin_label=&#8221;Text&#8221; _builder_version=&#8221;4.27.0&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221; sticky_enabled=&#8221;0&#8243;]<\/p>\n<div id=\"mk-text-block-475\" class=\"mk-text-block  \">\n<p><span><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/www.knome.com\/wp-content\/uploads\/2024\/09\/omixonFeature-2we28ekcmqyq0c5jlv2fwg.jpg\" width=\"151\" height=\"152\" alt=\"\" class=\"wp-image-100157 alignnone size-full\" style=\"float: left;\" srcset=\"https:\/\/www.knome.com\/wp-content\/uploads\/2024\/09\/omixonFeature-2we28ekcmqyq0c5jlv2fwg.jpg 249w, https:\/\/www.knome.com\/wp-content\/uploads\/2024\/09\/omixonFeature-2we28ekcmqyq0c5jlv2fwg-150x150.jpg 150w\" sizes=\"(max-width: 151px) 100vw, 151px\" \/>CAMBRIDGE, MA \u2014 June 3, 2013 \u2014 Knome Inc., the human genome interpretation company, today announced that its Services division will now provide its clients with advanced HLA typing capabilities as part of its whole genome and exome interpretation offerings. These capabilities will be powered by Omixon\u2019s Targeted HLA Typing technologies. Financial terms of the agreement were not disclosed.<\/span><\/p>\n<p>\u00a0The Human Leukocyte Antigen (HLA) genes are part of the immune system and play a role in number of areas, including infection, monogenic disorders, auto-immunity, cancer, transplantation, and drug response. HLA genes contain the genome\u2019s highest concentration of potential biomarkers, with specific HLA genotypes currently being investigated as biomarkers in 69 clinical trials.<\/p>\n<p>Despite its value, accurate and robust analysis of HLA genes has not been possible due to technical challenges related to repeated segments and pseudogenes significantly longer than the typical NGS read length of 150 to 250nt, a combination of extremely polymorphic exons and conserved regions, a haplotype structure, and phasing issues.<\/p>\n<p>\u201cOmixon has developed an excellent direct genotyping method from next generation sequencing that addresses the major problems associated with HLA calling,\u201d said Wolfgang Daum, CEO of Knome. \u201cThey\u2019ve developed industry-leading capabilities that we are very pleased to be able to incorporate into the informatics pipeline that powers our interpretation services offerings.\u201d<\/p>\n<p>\u201cKnome helps to discover safer and more efficient therapies by identifying genomic biomarkers for drug response and adverse response,\u201d said Attila Berces, CEO of Omixon.\u201d \u201cThus, pharmaceutical companies can shorten the time to approval and reduce the risk of late-stage failures. Omixon is proud to contribute to Knome\u2019s interpretation services by helping to understand HLA, which is a pharmacologically very important genomic region.\u201d<\/p>\n<p>&nbsp;<\/p>\n<\/div>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.0&#8243; _module_preset=&#8221;default&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221; sticky_enabled=&#8221;0&#8243;]<\/p>\n<p><b>About Knome<\/b><\/p>\n<p>Knome Inc. is a leading provider of human genome interpretation systems and services. Knome provides tools and solutions that help researchers, drug developers, and clinicians determine the genetic basis of human disease and drug response.\u00a0Designed to accelerate and industrialize the process of interpreting whole genomes, Knome\u2019s big data technologies are helping to pave the healthcare industry\u2019s transition to molecular-based, precision medicine.<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.0&#8243; _module_preset=&#8221;default&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221; sticky_enabled=&#8221;0&#8243;]<\/p>\n<p><b>About\u00a0Omixon<\/b><\/p>\n<p>Omixon helps clinical, diagnostic and research labs to adopt\u00a0next generation sequencing for the benefit of patients, by providing accurate and validated data analysis software. Using the Omixon Target application suite scientists and clinicians are empowered to investigate challenging genomic regions, such the human leukocyte antigen (HLA), breast cancer susceptibility genes (BRCA1 and BRCA2), and cystic fibrosis gene (CFTR), as well as custom panels.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.27.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_text _builder_version=&#8221;4.27.0&#8243; _module_preset=&#8221;default&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221; sticky_enabled=&#8221;0&#8243;]<\/p>\n<div class=\"mk-single-content\">\n<div class=\"wpb_row vc_row-fluid  \">\n<div class=\"vc_span12 wpb_column column_container \">\n<div id=\"mk-text-block-111\" class=\"mk-text-block  \">\n<p align=\"center\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/www.knome.com\/wp-content\/uploads\/2024\/09\/f8d4fffc-ef75-48cb-b763-9e2e8f0a7c48-300x27.png\" width=\"300\" height=\"27\" alt=\"\" class=\"wp-image-100159 alignnone size-medium\" \/><\/p>\n<div class=\"clearboth\"><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"single-post-tags\"><\/div>\n<div class=\"single-back-top\"><\/div>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, MA \u2014 June 3, 2013 \u2014 Knome Inc., the human genome interpretation company, today announced that its Services division will now provide its clients with advanced HLA typing capabilities as part of its whole genome and exome interpretation offerings. These capabilities will be powered by Omixon\u2019s Targeted HLA Typing technologies. Financial terms of the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":100157,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"<img class=\"size-full wp-image-100015 alignleft\" src=\"https:\/\/www.knome.com\/wp-content\/uploads\/2024\/09\/GENALICE.jpg\" alt=\"\" width=\"300\" height=\"70\" \/>\r\n\r\nHARDERWIJK, the Netherlands and CAMBRIDGE, Mass \u2013 January 12, 2015 \u2013 Today GENALICE and Knome, Inc. USA jointly announced a strategic partnership to offer their products together as a turn-key solution for those using next-generation sequencing (NGS) data to interpret patients\u2019 genomes. GENALICE MAP is an ultra-fast and highly accurate preprocessing solution for aligning and calling NGS data and seamlessly connects to Knome\u2019s informatics and genomics interpretation system, the knoSYS<sup>\u00ae<\/sup>\u00a0platform.\r\n\r\nStated CEO and President of Knome, Wolfgang Daum, \u201cThe GENALICE and Knome partnership came about in response to the reality that the amount of NGS data and its increasing usage requires processing and interpreting at an incredible pace. Wide-spread implementation of sequencing in the clinic toward the goal of precision medicine will only make this fact more apparent.\u201d\r\n\r\nWhile both products will continue to be offered separately, customers wanting to take advantage of the combined system can expect a reduction of NGS data bottlenecks, improved ability to annotate and interpret human genomes, and unprecedented control over their data from end-to-end.\r\n\r\nHans Karten, CEO of GENALICE, commented, \u201cWhereas GENALICE MAP speeds up and improves the process of aligning and calling genomes, the knoSYS platform focuses on the annotation and interpretation piece. These two products complement each other beautifully in creating a workflow that eliminates many of the frustrations of wrangling NGS data today.\u201d\r\n\r\n<strong>About Knome, Inc.<\/strong>\r\nKnome, Inc. is a leading provider of human genome interpretation systems and services. Knome provides tools and solutions that help researchers, drug developers, and clinicians determine the genetic basis of human disease and drug response. Designed to accelerate and industrialize the process of interpreting whole genomes, Knome\u2019s big data technologies are helping to smooth the healthcare industry\u2019s transition to molecular-based, precision medicine.\r\n\r\n<strong>About GENALICE<\/strong>\r\nGENALICE is a highly innovative biomedical big data company, with global headquarters in the Netherlands. GENALICE designs and builds groundbreaking software solutions for ultra-fast, highly accurate and cost-effective DNA data processing and analysis on general-purpose hardware. With GENALICE MAP, it introduced the first Next-Generation Sequencing (NGS) data processing pipeline with true population power. By partnering with world-renowned research institutes and healthcare companies, GENALICE is committed to unlocking the potential of whole genome and exome sequencing for biomarker discovery and medical application. More information on GENALICE can be found at\u00a0<a href=\"http:\/\/www.genalice.com\/\" target=\"_blank\" rel=\"noopener\">www.genalice.com<\/a>.\r\n\r\n<strong>Media Contacts<\/strong>\r\n<div>Knome, Inc. USA\r\nJessica Vionas\r\nDirector of Marketing\r\n617-715-1000 x2012\r\njvionas@knome.com<\/div>\r\n<div>GENALICE B.V.\r\nJos Lunenberg\r\nChief Business Officer\r\n+31 88 1221 000\r\njos.lunenberg@genalice.com<\/div>\r\n<p align=\"center\">###<\/p>\r\n<p align=\"center\"><\/p>","_et_gb_content_width":"","footnotes":""},"categories":[1],"tags":[],"class_list":["post-100153","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-releases"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Omixon\/Knome Offer Advanced HLA Typing for Whole Genome &amp; Exome Data<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.knome.com\/?p=100153\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Omixon\/Knome Offer Advanced HLA Typing for Whole Genome &amp; Exome Data\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, MA \u2014 June 3, 2013 \u2014 Knome Inc., the human genome interpretation company, today announced that its Services division will now provide its clients with advanced HLA typing capabilities as part of its whole genome and exome interpretation offerings. These capabilities will be powered by Omixon\u2019s Targeted HLA Typing technologies. Financial terms of the [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.knome.com\/?p=100153\" \/>\n<meta property=\"og:site_name\" content=\"Knome | Genome Interpretation Systems &amp; Services\" \/>\n<meta property=\"article:published_time\" content=\"2013-06-03T17:55:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-12T13:29:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.knome.com\/wp-content\/uploads\/2024\/09\/omixonFeature-2we28ekcmqyq0c5jlv2fwg.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"249\" \/>\n\t<meta property=\"og:image:height\" content=\"250\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Jason Bailey\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jason Bailey\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.knome.com\\\/?p=100153#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.knome.com\\\/?p=100153\"},\"author\":{\"name\":\"Jason Bailey\",\"@id\":\"https:\\\/\\\/www.knome.com\\\/#\\\/schema\\\/person\\\/eb7b08ce3aec9801f4fc316c4122bed3\"},\"headline\":\"Omixon and Knome Partner to Offer Advanced HLA Typing for Whole Genome and Exome Level Data\",\"datePublished\":\"2013-06-03T17:55:44+00:00\",\"dateModified\":\"2024-09-12T13:29:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.knome.com\\\/?p=100153\"},\"wordCount\":698,\"image\":{\"@id\":\"https:\\\/\\\/www.knome.com\\\/?p=100153#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.knome.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/omixonFeature-2we28ekcmqyq0c5jlv2fwg.jpg\",\"articleSection\":[\"Press Releases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.knome.com\\\/?p=100153\",\"url\":\"https:\\\/\\\/www.knome.com\\\/?p=100153\",\"name\":\"Omixon\\\/Knome Offer Advanced HLA Typing for Whole Genome & Exome Data\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.knome.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.knome.com\\\/?p=100153#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.knome.com\\\/?p=100153#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.knome.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/omixonFeature-2we28ekcmqyq0c5jlv2fwg.jpg\",\"datePublished\":\"2013-06-03T17:55:44+00:00\",\"dateModified\":\"2024-09-12T13:29:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.knome.com\\\/#\\\/schema\\\/person\\\/eb7b08ce3aec9801f4fc316c4122bed3\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.knome.com\\\/?p=100153#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.knome.com\\\/?p=100153\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.knome.com\\\/?p=100153#primaryimage\",\"url\":\"https:\\\/\\\/www.knome.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/omixonFeature-2we28ekcmqyq0c5jlv2fwg.jpg\",\"contentUrl\":\"https:\\\/\\\/www.knome.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/omixonFeature-2we28ekcmqyq0c5jlv2fwg.jpg\",\"width\":249,\"height\":250},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.knome.com\\\/?p=100153#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.knome.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Omixon and Knome Partner to Offer Advanced HLA Typing for Whole Genome and Exome Level Data\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.knome.com\\\/#website\",\"url\":\"https:\\\/\\\/www.knome.com\\\/\",\"name\":\"Knome | Genome Interpretation Systems &amp; Services\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.knome.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.knome.com\\\/#\\\/schema\\\/person\\\/eb7b08ce3aec9801f4fc316c4122bed3\",\"name\":\"Jason Bailey\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/56bce6b92ef218a6b47a057c253c7c75450a6bb5a6b3e61df84aa47d5443f933?s=96&d=wavatar&r=x\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/56bce6b92ef218a6b47a057c253c7c75450a6bb5a6b3e61df84aa47d5443f933?s=96&d=wavatar&r=x\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/56bce6b92ef218a6b47a057c253c7c75450a6bb5a6b3e61df84aa47d5443f933?s=96&d=wavatar&r=x\",\"caption\":\"Jason Bailey\"},\"url\":\"https:\\\/\\\/www.knome.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Omixon\/Knome Offer Advanced HLA Typing for Whole Genome & Exome Data","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.knome.com\/?p=100153","og_locale":"en_US","og_type":"article","og_title":"Omixon\/Knome Offer Advanced HLA Typing for Whole Genome & Exome Data","og_description":"CAMBRIDGE, MA \u2014 June 3, 2013 \u2014 Knome Inc., the human genome interpretation company, today announced that its Services division will now provide its clients with advanced HLA typing capabilities as part of its whole genome and exome interpretation offerings. These capabilities will be powered by Omixon\u2019s Targeted HLA Typing technologies. Financial terms of the [&hellip;]","og_url":"https:\/\/www.knome.com\/?p=100153","og_site_name":"Knome | Genome Interpretation Systems &amp; Services","article_published_time":"2013-06-03T17:55:44+00:00","article_modified_time":"2024-09-12T13:29:03+00:00","og_image":[{"width":249,"height":250,"url":"https:\/\/www.knome.com\/wp-content\/uploads\/2024\/09\/omixonFeature-2we28ekcmqyq0c5jlv2fwg.jpg","type":"image\/jpeg"}],"author":"Jason Bailey","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Jason Bailey","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.knome.com\/?p=100153#article","isPartOf":{"@id":"https:\/\/www.knome.com\/?p=100153"},"author":{"name":"Jason Bailey","@id":"https:\/\/www.knome.com\/#\/schema\/person\/eb7b08ce3aec9801f4fc316c4122bed3"},"headline":"Omixon and Knome Partner to Offer Advanced HLA Typing for Whole Genome and Exome Level Data","datePublished":"2013-06-03T17:55:44+00:00","dateModified":"2024-09-12T13:29:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.knome.com\/?p=100153"},"wordCount":698,"image":{"@id":"https:\/\/www.knome.com\/?p=100153#primaryimage"},"thumbnailUrl":"https:\/\/www.knome.com\/wp-content\/uploads\/2024\/09\/omixonFeature-2we28ekcmqyq0c5jlv2fwg.jpg","articleSection":["Press Releases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.knome.com\/?p=100153","url":"https:\/\/www.knome.com\/?p=100153","name":"Omixon\/Knome Offer Advanced HLA Typing for Whole Genome & Exome Data","isPartOf":{"@id":"https:\/\/www.knome.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.knome.com\/?p=100153#primaryimage"},"image":{"@id":"https:\/\/www.knome.com\/?p=100153#primaryimage"},"thumbnailUrl":"https:\/\/www.knome.com\/wp-content\/uploads\/2024\/09\/omixonFeature-2we28ekcmqyq0c5jlv2fwg.jpg","datePublished":"2013-06-03T17:55:44+00:00","dateModified":"2024-09-12T13:29:03+00:00","author":{"@id":"https:\/\/www.knome.com\/#\/schema\/person\/eb7b08ce3aec9801f4fc316c4122bed3"},"breadcrumb":{"@id":"https:\/\/www.knome.com\/?p=100153#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.knome.com\/?p=100153"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.knome.com\/?p=100153#primaryimage","url":"https:\/\/www.knome.com\/wp-content\/uploads\/2024\/09\/omixonFeature-2we28ekcmqyq0c5jlv2fwg.jpg","contentUrl":"https:\/\/www.knome.com\/wp-content\/uploads\/2024\/09\/omixonFeature-2we28ekcmqyq0c5jlv2fwg.jpg","width":249,"height":250},{"@type":"BreadcrumbList","@id":"https:\/\/www.knome.com\/?p=100153#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.knome.com\/"},{"@type":"ListItem","position":2,"name":"Omixon and Knome Partner to Offer Advanced HLA Typing for Whole Genome and Exome Level Data"}]},{"@type":"WebSite","@id":"https:\/\/www.knome.com\/#website","url":"https:\/\/www.knome.com\/","name":"Knome | Genome Interpretation Systems &amp; Services","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.knome.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.knome.com\/#\/schema\/person\/eb7b08ce3aec9801f4fc316c4122bed3","name":"Jason Bailey","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/56bce6b92ef218a6b47a057c253c7c75450a6bb5a6b3e61df84aa47d5443f933?s=96&d=wavatar&r=x","url":"https:\/\/secure.gravatar.com\/avatar\/56bce6b92ef218a6b47a057c253c7c75450a6bb5a6b3e61df84aa47d5443f933?s=96&d=wavatar&r=x","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/56bce6b92ef218a6b47a057c253c7c75450a6bb5a6b3e61df84aa47d5443f933?s=96&d=wavatar&r=x","caption":"Jason Bailey"},"url":"https:\/\/www.knome.com\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/www.knome.com\/index.php?rest_route=\/wp\/v2\/posts\/100153","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.knome.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.knome.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.knome.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.knome.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=100153"}],"version-history":[{"count":3,"href":"https:\/\/www.knome.com\/index.php?rest_route=\/wp\/v2\/posts\/100153\/revisions"}],"predecessor-version":[{"id":100160,"href":"https:\/\/www.knome.com\/index.php?rest_route=\/wp\/v2\/posts\/100153\/revisions\/100160"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.knome.com\/index.php?rest_route=\/wp\/v2\/media\/100157"}],"wp:attachment":[{"href":"https:\/\/www.knome.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=100153"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.knome.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=100153"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.knome.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=100153"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}